We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

LDC and Qurient Close License Agreement on Novel Anti-cancer Compound

News   Jun 04, 2015

 
LDC and Qurient Close License Agreement on Novel Anti-cancer Compound
 
 
 

RELATED ARTICLES

Alzheimer's Trafficking Defect Corrected in Rodents

News

UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.

READ MORE

Immune System Kept in Check by Protein Police

News

Researchers learn how a key transcription factor helps regulate the immune system and could be critical to understanding autoimmune disease and cancer immunosuppression.

READ MORE

How Anti-psychotic Medications Drive Weight Gain

News

About three million Americans take antipsychotic medications for conditions such as bipolar disorder, PTSD and schizophrenia. These medications are vital for mental health, yet many people stop taking them because of the side effects of weight gain and associated metabolic diseases.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE